Compare Multifiling Mitra Indonesia Tbk. (MFMI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Multifiling Mitra Indonesia Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Multifiling Mitra Indonesia Tbk. trades at Rp1,300 (market cap 984.86B), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Multifiling Mitra Indonesia Tbk. is far larger — about 9.4× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| MFMI | SCPI | |
|---|---|---|
Market Cap | 984.86B | 104.4B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Multifiling Mitra Indonesia Tbk.
PT Multifiling Mitra Indonesia Tbk (the Company) was established based on the Notarial Deed No. 157 of Misahardi Wilamarta, SH., dated July 9, 1992. MMI is a joint venture company between PT.Multipolar Corp. Tbk. and PT. Lippo Karawaci Tbk, currently serving its customers in 4-big city, Jakarta, Surabaya, Medan dan Bandung.
Read more on MFMI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
